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Development of biodegradable polymer based 
tamoxifen citrate loaded nanoparticles and effect 
of some manufacturing process parameters on 
them: a physicochemical and in-vitro evaluation
Abstract: The aim of the present study was to develop nanoparticles of tamoxifen 
citrate, a non-steroidal antiestrogenic drug used for the treatment of breast cancer. Biodegradable 
poly (D, L- lactide-co-glycolide)-85:15 (PLGA) was used to develop nanoparticles of tamoxifen 
citrate by multiple emulsification (w/o/w) and solvent evaporation technique. Drug-polymer 
ratio, polyvinyl alcohol concentrations, and homogenizing speeds were varied at different stages 
of preparation to optimize the desired size and release profile of drug. The characterization of 
particle morphology and shape was performed by field emission scanning electron microscope 
(FE-SEM) and particle size distribution patterns were studied by direct light scattering method 
using zeta sizer. In vitro drug release study showed that release profile of tamoxifen from biode-
gradable nanoparticles varied due to the change in speed of centrifugation for separation. Drug 
loading efficiency varied from 18.60% to 71.98%. The FE-SEM study showed that biodegradable 
nanoparticles were smooth and spherical in shape. The stability studies of tamoxifen citrate in 
the experimental nanoparticles showed the structural integrity of tamoxifen citrate in PLGA 
nanoparticles up to 60°C in the tested temperatures. Nanoparticles containing tamoxifen citrate 
could be useful for the controlled delivery of the drug for a prolonged period.
Keywords: biodegradable, nanoparticles, PLGA, stability, tamoxifen citrate
Introduction
Cancer is a major human health problem worldwide and it is the second leading cause of 
death in USA.1,2 Breast cancer is the most fatal disease especially for women worldwide. 
tamoxifen, a non-steroidal antiestrogen and a selective estrogen receptor modulator, has been 
the clinical choice for the antiestrogenic treatment of metastasis or advanced breast cancer for 
more than 20 years.2 It is used as adjuvant or additional therapy following primary treatment 
for early stage breast cancer3–5 and to treat post menopausal breast cancer.6,7 Nanoparticles 
as drug delivery systems are rapidly expanding area in drug delivery sciences. Tremendous 
opportunities1 exist for using nanoparticles as controlled drug delivery systems for cancer 
treatment.8,9 Results of scientific efforts to develop tamoxifen citrate-loaded nanoparticles/
microparticles using various polymers, both natural and synthetic, have been available in 
the literature.10–15 PLGA or poly (lactic-co-glycolic acid) is one of approved polymers by the 
US Food and Drug Administration (FDA) for human use as surgical sutures, implantable 
devices, and drug delivery systems, owing to its biodegradability and biocompatibility.16 
  Depending on the ratio of lactides to glycolides used for the polymerization, different forms 
of PLGA can be obtained and it undergoes hydrolysis in the body to produce the original 
Basudev Sahana 
Kousik Santra 
Sumit Basu 
Biswajit Mukherjee
Department of Pharmaceutical 
Technology, Jadavpur University,  
Kolkata, India
Correspondence: Biswajit Mukherjee 
Department of Pharmaceutical 
Technology, Jadavpur University, Kolkata 
700 032, India 
Tel +91 33 24146677 
Fax +91 33 24146677 
Email biswajit55@yahoo.comInternational Journal of Nanomedicine 2010:5 622
Sahana et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
monomers, lactic acid, and glycolic acid. These two monomers 
under normal physiological conditions are byproducts of various 
metabolic pathways in the body. Since the body effectively deals 
with the two monomers, there is very minimal systemic toxicity 
associated with using PLGA for drug delivery or biomaterial 
applications.17 PLGA-based nanoparticles containing several 
types of drugs including anticancer drugs have been reported 
as unique to this type of formulation.1 Enhanced systemic 
stability of drugs or therapeutics, continuous and controlled drug 
release, reduced dosage and decrease in systemic side effects, 
reduced possibility of dose dumping, reduced frequency of 
administration and therefore increased patient compliance are 
some of the advantages of sustained release nanoparticles based 
on biodegradable polymers such as PLGA.18 PLGA has different 
varieties with different characteristics based on the molar ratio 
of L-lactides and glycolides in PLGA. Presence of more lactides 
and less glycolides in PLGA (85:15) as compared to the other 
varieties of PLGA such as PLGA (75:25), PLGA (65:35), and 
PLGA (50:50), copolymer PLGA (85:15) showed slower release 
because of its high molecular weight and less hydrophilicity as 
compared to the other varieties of PLGA. Increased entrapment 
efficiency was observed for particles of PLGA (85:15) than the 
PLGA with lower L-lactide moiety,19 which ultimately could 
suggest more loading of drug in the co-polymer. Further, nano-
particles made of PLGA (85:15) without drug were showed to 
produce nanoparticles of lower polydispersity index than PLGA 
with less L-lactide content.19 Because of the higher molecular 
weight, PLGA (85:15) was found to produce particles of much 
smaller sizes as compared to the PLGA of other available variet-
ies, using the same preparation technique.20 Therefore an effort 
was made here to develop and evaluate (in vitro) biodegradable 
PLGA-(85:15) based nanoparticles for providing sustained 
release of tamoxifen citrate for breast cancer therapy.
Materials
Tamoxifen citrate was obtained as a gift sample from Khan-
delwal Pharmaceutical (Mumbai, India). Biodegradable 
polymer poly (D, L-lactide-co-glycolide)-85:15 (PLGA) 
from Sigma-Aldrich (Bangalore, India) and dichloromethane 
and methanol from Merck (Mumbai, India) were purchased. 
Polyvinyl alcohol (M.W.1,25,000) (PVA) was procured from 
SD Fine-Chem Pvt Ltd (Mumbai, India). All other chemicals 
used were of analytical grade.
Methodology
The biodegradable polymer poly (D, L-lactide-co-  glycolide)-
85:15 (PLGA) based nanoparticles containing tamoxifen 
citrate was prepared by water-in-oil-in-water (w/o/w) 
emulsification and solvent evaporation method.21,22 Initially 
numbers of different formulations were prepared by vary-
ing different manufacturing parameters and few selective 
successful formulations in terms of physicochemical 
evaluation data have been reported here. At first, the weighed 
amount of the polymer PLGA was dissolved in dichloro-
methane and tamoxifen citrate was solubilized in methanol. 
The drug and polymer solutions were mixed in a 10 mL 
beaker and then aqueous phase containing polyvinyl alcohol 
with specific concentration was added drop-wise into the 
oil phase and homogenized in a high speed homogenizer in 
specific optimized speed for 4 minutes (Tables 1 and 2). The 
primary emulsion (w/o) was formed. The primary emulsion 
was then added drop-wise into the aqueous phase contain-
ing PVA with specific concentrations and homogenized 
in the same speed for 6 minutes and a multiple emulsion 
(w/o/w) was formed. The prepared emulsion was placed 
on a magnetic stirrer and stirred for 12 hours at room 
temperature for the evaporation of organic solvent such 
as dichloromethane and methanol. Nanoparticles obtained 
were filtered, washed in a cooling centrifuge (Remi, 
Mumbai, India) at 4°C and kept in an ultra-low freezer 
(So-Low, Environmental Equipment, Cincinnati, Ohio, 
USA) at −80°C and dried in a freeze drier (IIC Industrial 
Corporation, Kolkata, India) at −42°C for 8 hours.
Nanoparticle evaluation  
and characterization
Drug–excipient interaction study  
using FTIR spectroscope
The pure drug tamoxifen citrate, PLGA-85:15, PVA, 
a mixture of PLGA and PVA, and a mixture of tamoxifen 
citrate, PLGA, and PVA; and a freshly prepared formulation 
were mixed separately with IR grade KBr in the ratio of 
1:100 and corresponding pellets were prepared by applying 
5.5 metric ton pressure with a hydraulic press. The pellets 
were scanned in an inert atmosphere over a wave number 
range of 4000–400 cm−1 in Magna IR 750 series II, FTIR 
instrument (Nicolet, Madison, WI, USA). However, due to 
Table 1 Polymer–drug composition of nanoparticles
Batch nr Tamoxifen citrate (mg) PLGA (mg)
BS-1 5 238
BS-2 5 240
BS-3 10 512International Journal of Nanomedicine 2010:5 623
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Table 2 Percentage yield and loading efficiency of the experimental formulations
Formulation 
code
Speed of  
homogenization 
(rpm)
Speed of  
centrifugation  
for separation (rpm)
Yield (%) Loading efficiency (%) 
(mean ± SD, n = 3)
Polydispersity   
index (PDI)
BS-1LS 16000 5000 44.07 33.16 ± 0.16 0.02
BS-2LS 16000 5000 44.86 36.35 ± 0.87 0.03
BS-3LS 16000 5000 88.86 71.98 ± 1.58 0.02
BS-1HS 16000 14000 21.17 18.60 ± 0.16 0.03
BS-2HS 16000 14000 25.56 20.84 ± 0.17 0.03
BS-3HS 16000 14000 58.19 50.75 ± 0.85 0.04
space constraint, we have shown here only the important 
spectra (Figure 1).
Percentage of yield
The lyophilized nanoparticles from each formulation were 
weighed and the respective percentage yield was calculated 
using the following formula.
 
Percentage yield =
weight of nanoparticles obtained
Total wei ight of drug and polymers used
× 100
 
Drug content study
Nanoparticles (2 mg) were dispersed in 1 mL of 0.1 M 
NaOH aqueous solution containing 5% w/v sodium dodecyl 
sulphate (SDS) and the mixture was shaken for 2–3 hours in 
an incubator shaker at 37°C. Drug from nanoparticles was 
extracted. The extracts were filtered by centrifugation and 
0.8 mL of supernatant was taken with the help of micropi-
pette and absorbance was noted using spectrophotometer 
at 275 nm. The drug entrapment efficiency was determined 
from the calibration curve prepared earlier using the fol-
lowing formula.
Percentage of drug entrapment efficiency =
(weight of the dr rug in 1 mg of product   total weight of formulation)
Tota
×
l l drug taken for formulation of a particular batch
×100
Surface morphology  
of nanoparticles
The surface morphology of nanoparticles was investi-
gated using Field Emission Scanning Electron Microscope 
(FESEM). Nanoparticle samples were mounted on the stubs 
using double-sided adhesive tapes. The stubs were then 
vacuum-coated with platinum using JEOL JFC 1600 autofine 
coater (JEOL, Tokyo, Japan). The nanoparticles were examined 
with FESEM, JEOL JSM 6700F (JEOL, Tokyo, Japan).
Particle size distribution
The characterization of particle size distribution was per-
formed by using Zetasizer nano ZS with DTS software 
(Malvern Instruments Limited, UK). NIBS® (non-invasive 
backscatter optics) technology was used for measurements of 
particles. The formulations were taken in lyophilized form in 
microcentrifuge tubes, suspended in phosphate buffer, pH 7.4 
and introduced in the instrument to read the results.
In vitro drug release study
Nanoparticles (3 mg) containing tamoxifen citrate were 
taken in 1 mL phosphate buffer, pH 7.4, in 2 mL Eppendorf 
tube and kept in an incubator shaker at 37°C. Numbers of 
such tubes were kept for analysis of drug release at different 
time points. At a particular time point the tubes intended for 
analysis (at that point) were taken out and the remaining tubes 
to be analyzed at their respective time points were left in the 
incubator shaker. Then the tubes were centrifuged at 5000 rpm 
for 10 minutes; the supernatant was taken and analyzed 
spectrophotometrically at 275 nm. Amount of drug released 
was determined from the calibration curve prepared earlier.
Stability study
Following the ICH guidelines, nanoparticles containing 
tamoxifen citrate samples were stored at elevated 
temperatures and relative humidity (25 ± 2°C/60% RH, 
45 ± 2°C/75% RH, 60 ± 2°C/75% RH ) in a stability 
analysis chamber (Darwin Chambers Company, St Louis, 
USA) over a period of 3 months.23 Samples stored at 2–8°C 
were used as control. Samples were kept for 3 months for 
stability analysis and after 3 months, FTIR spectra of drug 
of the nanoparticles were compared with those of the con-
trol formulations.
Results
Yield percentage and loading efficiency were found to vary 
with a variation in speed of centrifugation (Table 2). Yields International Journal of Nanomedicine 2010:5 624
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Figure 1 FTIR spectra of A) tamoxifen citrate; B) PLGA; C) mixture of drug and excipients; D) freshly prepared nanoparticles in the formulation (BS-3HS).International Journal of Nanomedicine 2010:5 625
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were more in case of the formulations (BS-1LS, BS-2LS, and 
BS-3LS) exposed to lower speed of centrifugation. Highest 
respective yield (%) values were obtained (both in high and 
low centrifugal speeds) in case of the formulations BS-3LS 
and BS-3HS. A similar trend was noticed in case of the loading 
efficiency also. Highest loading efficiency percentage (both in 
high and low centrifugal speeds of separation) was obtained 
for BS-3LS and BS-3HS in the respective category as com-
pared to the other experimental formulations. Drug–excipient 
interactions as determined by FTIR spectra (Figures 1, A–D) 
suggest that there were physical interactions between drug and 
excipients at the level of functional groups between 1300 and 
1200 cm−1 wave numbers. SEM photographs (Figures 2, A–F) 
show that the nanoparticles were densely dispersed with a 
narrow range of dispersion. Particles were of nano size with 
smooth surface. With the particle size analyzer the average 
diameter of particles for BS-3LS and BS-3HS were found 
to be 550 nm and 276 nm (Figure 3, A and B). In vitro drug 
release patterns were similar in all the formulations (Figure 4). 
Initial burst release was followed by sustained release of drug 
with the progress of time. Further the nanoparticles prepared 
with low speed centrifugation released the drug in slower pat-
terns as compared to those exposed to higher centrifugal force. 
Drug stability in the formulations as assessed by comparing 
the FTIR spectra of stored formulations (Figures 5, A–E) 
with the freshly prepared formulation (Figure 1D) revealed 
that there was no physicochemical interaction due to storage 
occurred in the formulations stored up to 25°C. However, at 
45°C and 60°C mild physical interactions as compared to the 
freshly prepared samples were detected.
Discussion
Yield (%) of various experimental nanoparticles were 
between 21.17% and 88.86% (Table 2). Therefore, the loss of 
yield was observed in nanoparticle preparations using PLGA 
and tamoxifen citrate. It might be due to recovery problem. 
The loss of yield might be due to adherence of highly viscous 
primary emulsion (w/o) (which was also sticky in nature) 
on the surface of the inner wall of the homogenizer and was 
not fully recovered. Loading efficiency of the experimental 
nanoparticles was found to vary significantly (P  0.05) 
as assessed by ANOVA followed by Tukey HSD Test. The 
variation in loading efficiency might be due to separation 
of smaller particles at higher centrifugal speed, which could 
entrap a smaller amount of drug.
Batches (BS-1LS, BS-2LS, and BS-3LS) separated at 
lower centrifugal speed (5000 rpm) had higher drug entrap-
ment as compared to those (BS-1HS, BS-2HS, and BS-3HS) 
separated at higher centrifugal speed (14,000 rpm). In real-
ity the speeds of centrifugation were determined by several 
experiments using the speeds of centrifugation ranging from 
4000 rpm to 20,000 rpm. Similar trends have been obtained 
throughout. However we have reported here the effect of two 
different speeds of centrifugation, which influenced all the 
parameters of the formulations   predominantly.
Drug–excipient interaction
Figure 1 (A–D) shows the FTIR spectra of tamoxifen citrate, 
PLGA and PVA (excipients), and mixture of drug and excipi-
ents and a freshly prepared formulation. Variation in peaks 
was noticed between 1300 and 1200 wave numbers (cm−1) 
in nanoparticles. The region is the IR stretching vibration 
zone of functional groups such as C-O (alcohol) and C-N.21 
Formation of weak physical bonds such as hydrogen bonding, 
bond due to Van der Waals forces or dipole moment might 
take place between C-N present in the drug molecule and 
2OH present in PLGA. The data suggest that there was no 
chemical interaction between the drug and the excipients 
since no shifting of characteristic peaks of drug as well as 
excipients was noticed as the shifting of characteristic peak 
is claimed as chemical interaction.24
Scanning electron microscopic study
SEM photographs (Figures 2, A–F) show the particle size 
distribution pattern of nanoparticle formulations. The 
  figure shows that PLGA nanoparticles containing tamoxifen 
citrate were spherical and of smooth surface.
Particle size distribution
Although we showed data of all six different formulations 
so far, we here now limit ourselves to formulations BS-3LS 
and BS-3HS, since they had the highest amount of loading 
and yield values. Figure 3 shows that the average particle size 
was about 550 nm (Figure 3A) with a polydispersity index 
(PDI) of 0.02 of the sample formulation obtained from low 
speed centrifugation (5000 rpm). Figure 3B shows that the 
average particle size of the nanoparticles was 276 nm for 
the formulation BS-3HS (PDI 0.04). Thus, the high speed of 
centrifugation used here was able to separate nanoparticles of 
smaller range with a lower polydispersion. The polydispersity 
indices suggest that particles were in nano-size range only 
with a narrow range of particle size distribution.
In vitro drug release study
Tamoxifen citrate was released from PLGA nanoparticles 
(Figure 4) following ‘bi-phasic’ pattern with an initial ‘burst International Journal of Nanomedicine 2010:5 626
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Figure 2 Scanning electron microscopy of PLGA nanoparticles A) BS-1LS; B) BS-1HS; C) BS-2LS; D) BS-2HS; E) BS-3LS; F) BS-3HS.International Journal of Nanomedicine 2010:5 627
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release’ of loosely bound tamoxifen citrate on/or near the 
surface of particles and then release of the remaining drug 
from the core due to diffusion and as the polymer matrix 
disintegrated. The release profile of the various samples 
were similar, ie, the primary burst release was followed by a 
sustained release. The differences in sustained release of the 
various samples might also be due to the nanoparticles with 
variable sizes, which varied surface areas as well as tortuosity 
of drug diffusion pathways in the nanoparticles. Drug release 
patterns were more or less linear as the duration of release 
progressed. BS-1LS showed the slowest drug release whereas 
BS-1HS showed the fastest drug release among the formula-
tions studied. Similar trends of drug release were also obtained 
for the other two (LS and HS) formulations. It could be that due 
to the exposure of high centrifugal force in BS-1HS, loosely 
bound drug molecules had come more from the core towards 
the surface and this resulted in a faster drug release.
Stability study
For stability study of the drug in formulations, the samples 
were kept at different temperatures (at 25°C, 45°C, and 
60°C) for 90 days following ICH guidelines23 and spectra of 
the formulation were determined by FTIR spectroscopy and 
compared with those of the freshly prepared formulations. 
Figure 5 (A–E) represents the IR spectra of the formulations 
that were kept at different temperatures for 90 days. Figure 1D 
represents the spectrum of freshly prepared formulation and 
Figures 1D and 5A and B were used as controls. Figures 5, 
C–E were compared with   Figure 5B. No variation of spectra 
of the samples stored at 25°C suggests that the drug remained 
stable in the formulations at those storage conditions and 
there was no physicochemical interaction between the drug 
and the excipients of nanoparticles under the storage condi-
tion. Variation in the FTIR spectra of the samples stored at 
45°C and 60°C suggests that in those formulations drug 
might have physically interacted with the excipients. This 
may help the slower release of drug from the formulations. 
However, this would not degrade the drug chemically in the 
nanoparticles since physical interactions in presence of humid 
environment at those temperatures are believed to occur due 
to the formation of weak physical bonds such as hydrogen 
bonding, bond due to Van der Waals forces or dipole-dipole 
interactions.
Conclusion
The prepared nanoparticles had good entrapment and rea-
sonable loading of the drug with controlled and prolonged 
release of tamoxifen citrate for the betterment of breast cancer 
therapy. Thus the mentioned nanoparticles could be beneficial 
to deliver tamoxifen citrate in a long-term controlled release 
pattern for the treatment of breast cancer. It may be a potential 
alternative dosage form of the drug for the treatment of breast 
cancer and further studies are warranted.
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